NEW YORK, May 02, 2018 /PRNewswire/ --
WallStEquities.com strives to bring the best free research to the investmentcommunity. Today we are offering reports on PODD, IART, MZOR, and MBOT which can be accessed for free by signing up to www.wallstequities.com/registration. On Tuesday, May 01, 2018, the NASDAQ Composite ended the trading
Billerica, Massachusetts headquartered Insulet Corp.'s stock finished Tuesday's session 1.26% higher at $87.08 with a total trading volume of 346,375 shares. The Company's shares have advanced 12.72% in the previous three months and 98.77% over the past twelve months. The stock is trading above its 50-day and 200-day moving averages by 4.77% and 27.03%, respectively. Additionally, shares of Insulet, which develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the US and internationally, have a Relative Strength Index (RSI) of 58.78.
On April 20th, 2018, research firm Berenberg initiated a 'Buy' rating on the Company's stock, with a target price of $100 per share. Get the full research report on PODD for free by clicking below at: www.wallstequities.com/registration/?symbol=PODD
Integra LifeSciences Holdings
On Tuesday, shares in Plainsboro, New Jersey headquartered Integra LifeSciences Holdings Corp. recorded a trading volume of 476,902 shares. The stock ended the session 1.01% higher at $62.25. The Company's shares have advanced 15.17% in the last month, 17.85% in the previous three months, and 35.36% over the last twelve months. The stock is trading above its 50-day and 200-day moving averages by 12.49% and 21.21%, respectively. Moreover, shares of Integra LifeSciences, which develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery, have an RSI of 74.05. Get access to our top-rated research, including the free report on IART at: www.wallstequities.com/registration/?symbol=IART
Caesarea, Israel-based Mazor Robotics Ltd's shares closed the day 0.11% lower at $53.05. The stock recorded a trading volume of 200,748 shares. The Company's shares have gained 44.16% over the last twelve months. The stock is trading below its 50-day moving average by 14.97%. Additionally, shares of Mazor Robotics, which together with its subsidiaries, engages in the development, production, and marketing of medical devices for supporting surgical procedures in the fields of orthopedics and neurosurgery in the US and internationally, have an RSI of 33.70. Click here to subscribe for a free membership which welcomes you with our report on MZOR at: www.wallstequities.com/registration/?symbol=MZOR
Shares in Yokneam, Israel-based Microbot Medical Inc. finished 2.95% lower at $0.79. The stock recorded a trading volume of 76,618 shares. The Company's shares have advanced 18.76% in the last month. The stock is trading above its 50-day moving average by 1.99%. Furthermore, shares of Microbot Medical, which researches, designs, and develops next generation micro-robotics assisted medical technologies targeting the minimally invasive surgery space, have an RSI of 52.31. Join our big investor community at Wall St. Equities today and get your free report on MBOT at: www.wallstequities.com/registration/?symbol=MBOT
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: email@example.com Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/stock-review-for-medical-supplies-investors----insulet-integra-lifesciences-mazor-robotics-and-microbot-medical-300640976.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!